Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia.

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Hyperprolactinaemia is commonly treated with low-dose cabergoline.
• Concerns exist regarding dopamine agonist valvulopathy, leading to strict surveillance guidelines.
• The Medicines and Healthcare products Regulatory Agency (MHRA) recommends annual echocardiography.

Purpose of the Study:

• To review the evidence on cardiac valvulopathy risk in patients on low-dose cabergoline.
• To evaluate the current screening guidelines for dopamine agonist valvulopathy.
• To assess the cost-effectiveness and resource implications of current surveillance strategies.

Main Methods:

• Literature review of pathophysiological mechanisms of dopamine agonist valvulopathy.
• Analysis of published data on the incidence of valvulopathy with low-dose cabergoline.
• Examination of current and historical evidence-based screening guidelines.

Main Results:

• Emerging evidence suggests a low risk of cardiac valvulopathy in patients on low-dose cabergoline.
• Strict adherence to annual echocardiography guidelines is costly (£5.76 million/year in the UK) and resource-intensive (90,000 extra echocardiograms/year).
• Fewer endocrinologists are strictly adhering to the MHRA guidance due to evolving evidence.

Conclusions:

• The current surveillance strategy for low-dose cabergoline in hyperprolactinaemia requires re-evaluation.
• Evidence supports a less stringent approach to echocardiography screening.
• Revised guidelines could reduce healthcare costs and resource utilization without compromising patient safety.